Study Shows Metformin May Reduce Risk of Blood Cancer
A recent study reveals that the diabetes drug metformin may reduce the risk of blood cancer, specifically myeloproliferative neoplasm (MPN). Apart from its primary function, metformin has shown potential in lowering the risk of colorectal, breast, and prostate cancers, as well as cancer-related death. The drug’s benefits also include anti-aging effects, weight loss, improved fertility in individuals with PCOS, and potential cardiovascular health enhancements.
Public Views and Usage of GLP-1 Drugs Revealed in Latest Health Tracking Poll
The latest KFF Health Tracking Poll reveals insights into public use and views of GLP-1 drugs, with 6% of adults currently using them for weight loss, diabetes, or heart disease. Despite increased awareness, affordability remains a concern, as 54% of adults find it challenging to cover costs. Usage is higher among adults with chronic conditions, highlighting accessibility and financial barriers faced by individuals seeking to benefit from GLP-1 drugs.
FDA issues Class I recall for t:connect iPhone app due to battery drain glitch in insulin pump
The FDA has issued a Class I recall for the t:connect iPhone app due to a software glitch that drained the batteries of the t:slim X2 insulin pump, leading to potential pump shutdowns. Consumers are advised to monitor pump battery levels closely and update to version 2.7.1 or later to prevent unexpected shutdowns and health risks associated with insulin delivery disruptions.
Metformin Shows Promise in Reducing SARS-CoV-2 Levels in Clinical Trial
A recent clinical trial by University of Minnesota researchers found that the common diabetes drug metformin can reduce SARS-CoV-2 levels in the body, potentially lowering the risk of rebound symptoms. The study focused on standard-risk individuals and showed that metformin could decrease viral load, prevent hospitalization or death, and reduce the incidence of long COVID. Early intervention with metformin led to a 3.6-fold reduction in viral load by day 10 and decreased the likelihood of hospitalization or death by 58% within 28 days.
Promising Results in Slowing Parkinson’s Disease Progression
French researchers conduct a one-year study using a GLP-1 receptor agonist, a drug similar to Ozempic, showing promising results in slowing the progression of Parkinson’s disease. This development brings hope to the half a million Americans diagnosed with the illness and offers a glimmer of hope for individuals affected by Parkinson’s disease.
Study Links Statins to Glucose Intolerance and Diabetes
A recent study from China has linked a deficiency in Clostridium bacteria in the gut microbiome to statin-induced glucose intolerance and diabetes. The research suggests that altered bile acid profiles may hinder glucose metabolism, but administering ursodeoxycholic acid (UDCA) could potentially counteract these adverse effects, providing hope for individuals concerned about the impact of statins on their metabolic health.
New Study Suggests Exercise Can Help Avoid Weight Regain After Stopping Weight Loss Drugs
Half of weight loss drug users stop treatment within a year, but a new study suggests exercise may prevent weight regain. GLP-1 receptor agonists like Ozempic can help patients lose 15% of body weight, but side effects lead to discontinuation. University of Copenhagen study found that those who exercised maintained weight loss, while those who didn’t regained 70% of lost weight, mostly in the form of fat.
Study Shows SGLT2 Inhibitors May Lower Risk of Kidney Stones in Adults with Type 2 Diabetes
A recent study published in JAMA Internal Medicine found that adults with type 2 diabetes may benefit from lower risk of nephrolithiasis by initiating SGLT2 inhibitors. The research compared the effects of different type 2 diabetes medications on the risk of developing kidney stones and found that SGLT2 inhibitors outperformed other medications in reducing the risk of nephrolithiasis. This finding could have significant implications for the treatment and management of type 2 diabetes, as kidney stones can be a serious complication for individuals with the condition.
5 Exercise Routines to Help Control Blood Sugar Levels
Struggling to control your blood sugar levels? Regular exercise is a powerful tool in managing and regulating blood sugar. Incorporate these 5 exercise routines into your daily life to help control blood sugar levels and improve overall well-being.
SGLT2 Inhibitors May Lower Risk of Kidney Stones in Type 2 Diabetes Patients
Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit…